/ARQT
ARQT Stock - Arcutis Biotherapeutics, Inc.
Healthcare|BiotechnologyNASDAQ
$28.01+0.83%
+$0.23 (+0.83%) • Dec 19
72
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.BUY
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.97
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).78
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.52
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+14.2%upside
Target: $31.99
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for ARQT
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$27.73 – $28.29
TARGET (TP)$32.00
STOP LOSS$25.77
RISK/REWARD1:1.8
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta1.70
52W High$31.77
52W Low$11.13
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $196.54M | $59.61M | $3.69M | N/A | N/A |
| Gross Profit | $177.41M | $54.62M | $2.93M | $-763,000 | $-455,000 |
| Gross Margin | 90.3% | 91.6% | 79.5% | N/A | N/A |
| Operating Income | $-128,397,000 | $-241,101,000 | $-301,627,000 | $-206,529,000 | $-136,645,000 |
| Net Income | $-140,039,000 | $-262,140,000 | $-311,458,000 | $-206,356,000 | $-135,678,000 |
| Net Margin | -71.3% | -439.8% | -8449.8% | N/A | N/A |
| EPS | $-1.16 | $-3.78 | $-5.66 | $-4.17 | $-3.80 |
Company Overview
Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis. The company is also developing ARQ-154, a topical foam formulation of roflumilast for the treatment of seborrheic dermatitis and scalp psoriasis; ARQ-252, a selective topical janus kinase type 1 inhibitor for hand eczema and vitiligo; and ARQ-255, a topical formulation of ARQ-252 designed to reach deeper into the skin in order to treat alopecia areata. The company was formerly known as Arcutis, Inc. and changed its name to Arcutis Biotherapeutics, Inc. in October 2019. Arcutis Biotherapeutics, Inc. was incorporated in 2016 and is headquartered in Westlake Village, California.
Visit WebsiteRating Distribution
Strong Buy
0%
Buy / Outperform
4
57%
Hold / Neutral
3
43%
Sell / Underperform
0%
Analyst Consensus🟡 Mixed
4 Bullish3 Neutral/Bearish
Price Targets
$17
Average Target
↓ 40.8% Downside
Now
$4
Low
$17
Average
$46
High
Based on 7 analysts
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| July 25th 2025 | Goldman | Initiation | Neutral | $18 |
| December 30th 2024 | H.C. Wainwright | Initiation | Buy | $19 |
| August 28th 2024 | Jefferies | Initiation | Buy | $15 |
| January 3rd 2024 | Mizuho | Upgrade | Buy | $8← $4 |
| October 26th 2023 | Mizuho | Downgrade | Neutral | $4← $57 |
| October 13th 2023 | Goldman | Downgrade | Neutral | $6← $32 |
| September 7th 2022 | Needham | Initiation | Buy | $46 |
Earnings History & Surprises
ARQTBeat Rate
74%
Last 19 quarters
Avg Surprise
+20.2%
EPS vs Estimate
Beats / Misses
14/5
Last 12 quarters
Latest EPS
$0.06
Q4 2025
EPS Surprise History
Q1 24
-10.8%
$-0.72vs$-0.65
Q2 24
+46.7%
$-0.32vs$-0.60
Q3 24
+12.5%
$-0.42vs$-0.48
Q4 24
+21.4%
$-0.33vs$-0.42
Q1 25
+67.9%
$-0.09vs$-0.28
Q2 25
+4.8%
$-0.20vs$-0.21
Q3 25
+27.8%
$-0.13vs$-0.18
Q4 25
+160.0%
$0.06vs$-0.10
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q1 2026 | Feb 24, 2026 | $0.02 | — | — | — |
Q4 2025 | Oct 28, 2025 | $-0.10 | $0.06 | +160.0% | ✓ BEAT |
Q3 2025 | Aug 6, 2025 | $-0.18 | $-0.13 | +27.8% | ✓ BEAT |
Q2 2025 | May 6, 2025 | $-0.21 | $-0.20 | +4.8% | ✓ BEAT |
Q1 2025 | Feb 25, 2025 | $-0.28 | $-0.09 | +67.9% | ✓ BEAT |
Q4 2024 | Nov 6, 2024 | $-0.42 | $-0.33 | +21.4% | ✓ BEAT |
Q3 2024 | Aug 14, 2024 | $-0.48 | $-0.42 | +12.5% | ✓ BEAT |
Q2 2024 | May 14, 2024 | $-0.60 | $-0.32 | +46.7% | ✓ BEAT |
Q1 2024 | Feb 27, 2024 | $-0.65 | $-0.72 | -10.8% | ✗ MISS |
Q4 2023 | Nov 3, 2023 | $-0.90 | $-0.73 | +18.9% | ✓ BEAT |
Q3 2023 | Aug 8, 2023 | $-1.22 | $-1.16 | +4.9% | ✓ BEAT |
Q2 2023 | May 9, 2023 | $-1.30 | $-1.31 | -0.8% | ✗ MISS |
Q1 2023 | Feb 28, 2023 | $-1.37 | $-1.18 | +13.9% | ✓ BEAT |
Q4 2022 | Nov 8, 2022 | $-1.54 | $-1.89 | -22.7% | ✗ MISS |
Q3 2022 | Aug 4, 2022 | $-1.38 | $-1.31 | +5.1% | ✓ BEAT |
Q2 2022 | May 5, 2022 | $-1.42 | $-1.27 | +10.6% | ✓ BEAT |
Q1 2022 | Feb 22, 2022 | $-1.41 | $-1.42 | -0.7% | ✗ MISS |
Q4 2021 | Nov 4, 2021 | $-1.09 | $-1.14 | -4.6% | ✗ MISS |
Q3 2021 | Aug 5, 2021 | $-0.91 | $-0.84 | +7.7% | ✓ BEAT |
Q2 2021 | May 4, 2021 | $-0.96 | $-0.76 | +20.8% | ✓ BEAT |
Latest News
Mizuho Maintains Outperform on Arcutis Biotherapeutics, Raises Price Target to $37
📈 PositiveBenzinga•Nov 28, 2025, 03:11 PM
Arcutis Says FDA Accepts sNDA For ZORYVE Cream 0.3% To Expand Indication For Topical Treatment Of Plaque Psoriasis To Include Children 2 To 5 Years Old; PDUFA Target Action Date Set For June 29, 2026
📈 PositiveBenzinga•Nov 17, 2025, 01:11 PM
Arcutis Completes Enrollment In INTEGUMENT-INFANT Phase 2 Study Of ZORYVE Cream 0.05% In Infants With Atopic Dermatitis
📈 PositiveBenzinga•Nov 13, 2025, 01:03 PM
Arcutis Canada Announces Health Canada Approval Of ZORYVE Foam 0.3% For Scalp And Body Psoriasis In Adults And Adolescents Ages 12 And Older
📈 PositiveBenzinga•Nov 13, 2025, 12:05 PM
Arcutis Biotherapeutics Publshes Long-Term Safety And Efficacy Data Of ZORYVE Foam 0.3% In Individuals With Seborrheic Dermatitis In American Journal Of Clinical Dermatology
📈 PositiveBenzinga•Nov 4, 2025, 01:04 PM
Goldman Sachs Maintains Neutral on Arcutis Biotherapeutics, Raises Price Target to $29
📈 PositiveBenzinga•Oct 30, 2025, 03:20 PM
Arcutis Biotherapeutics Announces Commercial Roll Out Of ZORYVE Cream To Treat Mild To Moderate Atopic Dermatitis In Children Ages 2 To 5 In U.S.
📈 PositiveBenzinga•Oct 30, 2025, 12:01 PM
Arcutis Biotherapeutics shares are trading higher after the company reported better-than-expected Q3 financial results.
📈 PositiveBenzinga•Oct 28, 2025, 03:01 PM
Arcutis Biotherapeutics Q3 EPS $0.06 Beats $(0.10) Estimate, Sales $99.219M Beat $86.978M Estimate
📈 PositiveBenzinga•Oct 28, 2025, 12:31 PM
Arcutis To Present ZORYVE Data At 2025 Fall Clinical Dermatology Conference Oct. 23-26
➖ NeutralBenzinga•Oct 24, 2025, 12:01 PM
FDA Approves Arcutis' ZORYVE Cream 0.05% For Atopic Dermatitis In Children Between 2 To 5
📈 PositiveBenzinga•Oct 6, 2025, 12:16 PM
Arcutis To Present New ZORYVE Foam Cream Data At European Academy Of Dermatology And Venereology Congress In Paris
📈 PositiveBenzinga•Sep 17, 2025, 08:38 AM
Arcutis Submits sNDA To Expand ZORYVE Cream Use For Plaque Psoriasis In Children As Young As 2
📈 PositiveBenzinga•Sep 3, 2025, 03:47 PM
Frequently Asked Questions about ARQT
What is ARQT's current stock price?
Arcutis Biotherapeutics, Inc. (ARQT) is currently trading at $28.01 per share. The stock has moved +0.83% today.
What is the analyst price target for ARQT?
The average analyst price target for ARQT is $32.00, based on 1 analyst.
What sector is Arcutis Biotherapeutics, Inc. in?
Arcutis Biotherapeutics, Inc. operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the NASDAQ exchange.
What is ARQT's market cap?
Arcutis Biotherapeutics, Inc. has a market capitalization of $3.43 billion, making it a mid-cap company.
Does ARQT pay dividends?
No, Arcutis Biotherapeutics, Inc. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorCELC
Celcuity Inc.
$101.16
Mkt Cap: $4.7B
CGON
CG Oncology, Inc. Common stock
$39.03
Mkt Cap: $2.9B
CNTA
Centessa Pharmaceuticals plc
$24.85
Mkt Cap: $3.3B
FOLD
Amicus Therapeutics, Inc.
$14.18
Mkt Cap: $4.4B
IRON
Disc Medicine, Inc.
$80.04
Mkt Cap: $3.0B
LEGN
Legend Biotech Corporation
$21.92
Mkt Cap: $2.0B
TARS
Tarsus Pharmaceuticals, Inc.
$81.40
Mkt Cap: $3.5B
TVTX
Travere Therapeutics, Inc.
$34.51
Mkt Cap: $3.1B
XENE
Xenon Pharmaceuticals Inc.
$44.10
Mkt Cap: $3.4B
ZLAB
Zai Lab Limited
$18.04
Mkt Cap: $2.0B
Explore stocks similar to ARQT for comparison